- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment change, Trial completion date, Trial termination, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Aug 28, 2018 P2, N=20, Terminated, Active, not recruiting --> Completed N=40 --> 20 | Trial completion date: Aug 2019 --> Aug 2018 | Recruiting --> Terminated; Slow accrual
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Trial completion, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Aug 24, 2017 P2, N=33, Completed, N=40 --> 1 | Initiation date: Aug 1998 --> Aug 1997 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed
- |||||||||| oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jul 2, 2017 P1, N=28, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial completion, Enrollment change, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - May 25, 2017 P1, N=7, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | N=70 --> 7 | Trial primary completion date: Jun 2016 --> Nov 2010
- |||||||||| oxaliplatin / Generic mfg., erlotinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed, Metastases: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer (clinicaltrials.gov) - Jun 29, 2016 P1, N=28, Active, not recruiting, Active, not recruiting --> Completed Completed --> Active, not recruiting
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016 P1, N=70, Active, not recruiting, Completed --> Active, not recruiting Trial primary completion date: Jun 2015 --> Jun 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015 P1, N=43, Completed, Completed --> Terminated; Slow accrual Active, not recruiting --> Completed
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Sep 22, 2015 P2, N=33, Active, not recruiting, Active, not recruiting --> Completed Trial primary completion date: Dec 2012 --> Dec 2014
- |||||||||| oxaliplatin / Generic mfg., irinotecan / Generic mfg., capecitabine / Generic mfg.
Biomarker, Enrollment closed, Metastases: Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer (clinicaltrials.gov) - Aug 13, 2015 P2, N=33, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015 Recruiting --> Active, not recruiting
- |||||||||| Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Enrollment open, Trial initiation date, Combination therapy, Metastases: FluoHeart: Effects of S-1 and Capecitabine on Coronary Artery Blood Flow (clinicaltrials.gov) - Apr 8, 2015 P2, N=40, Recruiting, Trial primary completion date: Dec 2014 --> Dec 2015 Not yet recruiting --> Recruiting | Initiation date: Aug 2014 --> Jan 2015
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014 P1, N=43, Active, not recruiting, Recruiting --> Active, not recruiting Phase classification: P1/2 --> P1
|